Résumé
T cells harboring multiple co-inhibitory molecules lose their anti-tumoral functionality. PD-1 is a clinically approved target in cancer therapy, but its expression alone does not mean dysfunctionality. The expression of Tim-3 on numerous cell types (T cell, Treg, dendritic cell, myeloid cells) favors tumor escape to immune cells. Within many tumors, PD-1/Tim-3 coexpressing CD8-T cells lose their ability to secrete cytokines (IFNγ, IL-2, TNFα) and their intratumoral infiltration correlates with a bad prognosis. Tim-3 recently appeared as a potential biomarker of anti-PD-1 resistance. Combined blockade of PD-1 and Tim-3 axis demonstrated potent clinical efficacy in preclinical models and reinforced the rationale of using an anti-Tim-3 to override tumor resistance.
Titre traduit de la contribution | Tim-3: A novel biomarker and therapeutic target in oncology |
---|---|
langue originale | Français |
Pages (de - à) | 231-237 |
Nombre de pages | 7 |
journal | Medecine/Sciences |
Volume | 34 |
Numéro de publication | 3 |
Les DOIs | |
état | Publié - 1 mars 2018 |
Modification externe | Oui |